Items Tagged ‘AstraZeneca’

November 9th, 2016

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer


AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients […]

View full entry

Tags: AstraZeneca, BRACAnalysis CDx, brca, lynparza, News, olaprarib, Ovarian Cancer, PARP enzyme, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer